3B Blackbio DX Q1 FY25 earnings call: Revenue & Margins
Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹19Cr
- +35.7% YoY
- −17.4% QoQ
- Net profit
- ₹11Cr
- +57.1% YoY
- +22.2% QoQ
- Margin
- 56%
- +11 pp YoY
- +13 pp QoQ
Guidance rank: #34 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on 3B Blackbio DX Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Total consolidated revenue for Q1 FY 2024-25: ₹2,312.50 lakh, up from ₹1,724.32 lakh in Q1 FY 2023-24. EBITDA Q1 FY 2024-25: Rs. 1,458.53 lakh.
From 3B Blackbio DX Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Total consolidated revenue for Q1 FY 2024-25: ₹2,312.50 lakh, up from ₹1,724.32 lakh in Q1 FY 2023-24.
- Diagnostics business standalone (non-COVID) sales rose to ₹1,496.92 lakh in Q1 FY 2024-25 from ₹1,054.13 lakh in Q1 FY 2023-24 (~42% increase).
- Molecular diagnostic (MDx) kits export sales increased to ₹346.93 lakh in Q1 FY 2024-25 from ₹163.51 lakh in Q1 FY 2023-24 (+112%).
- UK subsidiary TRUPCR® Europe Ltd. revenue grew 85% year-on-year in Q1 FY 2024-25 (from GBP 163,887 to GBP 309,204).
- Non-COVID sales effective growth for Q1 FY 2024-25 is approx. 40%, aligned with expected 20-25% growth outlook.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is continuously investing in additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 34).
- Funds will also be deployed in a joint venture created in Manchester, UK, depending on need (Page 34).
- The Manchester site houses sales, marketing, technical support, and R&D, with projected growth of 40%-50% for the fiscal year (Page 23).
- Expansion is ongoing and tied to strategic inorganic growth via acquisitions if financially viable, else share buybacks may be considered (Page 34).
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
3B Blackbio DX Ltd Q1 FY25 results — key figures
| ₹ Cr | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue | 19 | 14 | +35.7% | 23 | -17.4% |
| Operating profit (EBITDA) | 11 | 6 | +83.3% | 10 | +10% |
| Operating margin | 56% | 45% | +11 pp | 43% | +13 pp |
| Profit before tax | 14 | 9 | +55.6% | 14 | 0% |
| Net profit (PAT) | 11 | 7 | +57.1% | 9 | +22.2% |
| EPS (₹) | 12.97 | 9.71 | +33.6% | 10.33 | +25.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q1 FY25 results?
Total consolidated revenue for Q1 FY 2024-25: ₹2,312.50 lakh, up from ₹1,724.32 lakh in Q1 FY 2023-24. EBITDA Q1 FY 2024-25: Rs. 1,458.53 lakh.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 34).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
